载脂蛋白A1输注与急性心肌梗死后心血管结局
AEGIS-II是一项国际、双盲、安慰剂对照试验,纳入急性心肌梗死、多支冠状动脉病变且合并其他心血管危险因素的患者,随机接受每周4次6 g CSL112输注或匹配安慰剂,首次输注在急性心肌梗死首次医疗接触后5天内。主要终点为随机化至90天随访期间心肌梗死、卒中或心血管死亡的复合终点。共纳入18,219例患者(CSL112组9112例,安慰剂组9107例),90天主要终点事件风险无显著差异(CSL112组439例[4.8%] vs 安慰剂组472例[5.2%];HR 0.93;95%CI 0.81-1.05;P=0.24),180天(622例[6.9%] vs 683例[7.6%];HR 0.91;95%CI 0.81-1.01)和365天(885例[9.8%] vs 944例[10.5%];HR 0.93;95%CI 0.85-1.02)亦无显著差异。两组不良事件发生率相似,CSL112组超敏反应事件数更高。
要点
- 急性心肌梗死、多支冠状动脉病变且合并其他心血管危险因素的患者,每周4次6 g CSL112输注未降低90天主要终点风险(CSL112组4.8% vs 安慰剂组5.2%;HR 0.93;95%CI 0.81-1.05;P=0.24)。
- 180天主要终点:CSL112组6.9% vs 安慰剂组7.6%(HR 0.91;95%CI 0.81-1.01);365天:CSL112组9.8% vs 安慰剂组10.5%(HR 0.93;95%CI 0.85-1.02),均无显著差异。
- 两组不良事件发生率相似,但CSL112组超敏反应事件数更高。
- 首次CSL112输注在急性心肌梗死首次医疗接触后5天内给予,随后每周1次共4次,每次6 g。
适用人群与场景
- 急性心肌梗死、多支冠状动脉病变且合并其他心血管危险因素的患者。
处置流程与药物剂量
- CSL112组:每周1次静脉输注6 g CSL112,共4次,首次输注在急性心肌梗死首次医疗接触后5天内给予。
研究设计与关键结果
- 国际、双盲、安慰剂对照试验(AEGIS-II,NCT03473223),共纳入18,219例患者(CSL112组9112例,安慰剂组9107例)。
- 主要终点(随机化至90天随访期间心肌梗死、卒中或心血管死亡的复合终点):CSL112组439例(4.8%)vs 安慰剂组472例(5.2%);HR 0.93;95%CI 0.81-1.05;P=0.24,无显著差异。
- 180天主要终点:CSL112组622例(6.9%)vs 安慰剂组683例(7.6%);HR 0.91;95%CI 0.81-1.01。
- 365天主要终点:CSL112组885例(9.8%)vs 安慰剂组944例(10.5%);HR 0.93;95%CI 0.85-1.02。
- 两组不良事件发生率相似;CSL112组超敏反应事件数更高。
证据类型、等级与局限
- 证据类型:国际、双盲、安慰剂对照随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性心肌梗死、多支冠状动脉病变且合并其他心血管危险因素的患者,每周4次6 g CSL112输注未降低90天心肌梗死、卒中或心血管死亡风险,不支持在该人群中常规使用CSL112。
- CSL112组超敏反应事件数更高,输注期间需关注超敏反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
METHODS: We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up.
RESULTS: A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P = 0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group.
CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.).
参考来源
- Gibson CM, Duffy D, Korjian S, et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024. PMID: 38587254. doi:10.1056/NEJMoa2400969
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。